CYTK
CYTOKINETICS INC
Overview
Cytokinetics develops small molecule drugs designed to modulate muscle function for treating cardiovascular and neuromuscular diseases.
CYTOKINETICS INC is a Healthcare company operating in Biotechnology with a $10.75B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-05
- Q4 FY2025Earnings2026-02-2421 Q&A exchanges
- Q3 FY2025Earnings2025-11-0618 Q&A exchanges
- Q2 FY2025Earnings2025-08-0823 Q&A exchanges
- Q1 FY2025Earnings2025-05-0726 Q&A exchanges
- Q4 FY2024Earnings2025-02-2730 Q&A exchanges
- Q3 FY2024Earnings2024-11-0626 Q&A exchanges
- Q1 FY2024Earnings2024-05-0818 Q&A exchanges
- Q4 FY2023Earnings2024-02-2721 Q&A exchanges
- Q3 FY2023Earnings2023-11-0329 Q&A exchanges
- Q2 FY2023Earnings2023-08-0315 Q&A exchanges
- Q1 FY2023Earnings2023-05-0437 Q&A exchanges
- Q4 FY2022Earnings2023-03-0129 Q&A exchanges
- Q3 FY2022Earnings2022-11-0636 Q&A exchanges
- Q2 FY2022Earnings2022-08-0732 Q&A exchanges
- Q1 FY2022Earnings2022-05-0436 Q&A exchanges
- Q4 FY2021Earnings2022-02-2519 Q&A exchanges
- Q3 FY2021Earnings2021-11-0432 Q&A exchanges
- Q2 FY2021Earnings2021-08-0515 Q&A exchanges
- Q1 FY2021Earnings2021-05-0730 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-1.64—Rev— vs ——EODHD
- Q1 FY20262026-04-29EPS$-1.67 vs $-1.61-3.7%Rev$19.4M vs ——EODHD
- Q4 FY20252026-02-23EPS$-1.50 vs $-1.56+3.9%Rev$17.8M vs ——EODHD
- Q3 FY20252025-11-04EPS$-2.55 vs $-1.57-62.4%Rev$1.9M vs ——EODHD
- Q2 FY20252025-08-06EPS$-1.12 vs $-1.42+21.1%Rev$66.8M vs ——EODHD
- Q1 FY20252025-05-05EPS$-1.36 vs $-1.36+0.2%Rev$1.6M vs ——EODHD
- Q4 FY20242025-02-24EPS$-1.26 vs $-1.17-7.3%Rev$16.9M vs ——EODHD
- Q3 FY20242024-11-05EPS$-1.36 vs $-1.25-8.8%Rev$463.0K vs ——EODHD
- Q2 FY20242024-08-07EPS$-1.31 vs $-1.06-23.6%Rev$249.0K vs ——EODHD
- Q1 FY20242024-05-07EPS$-1.33 vs $-1.14-16.7%Rev$835.0K vs ——EODHD
- Q4 FY20232024-02-26EPS$-1.38 vs $-0.97-42.3%Rev$1.7M vs ——EODHD
- Q3 FY20232023-11-01EPS$-1.35 vs $-0.74-82.4%Rev$378.0K vs ——EODHD
- Q2 FY20232023-08-02EPS$-1.34 vs $-1.15-16.5%Rev$867.0K vs ——EODHD
- Q1 FY20232023-05-03EPS$-1.38 vs $-1.20-15.0%Rev$4.6M vs ——EODHD
- Q4 FY20222023-02-28EPS$-1.45 vs $-1.21-19.8%Rev$2.0M vs ——EODHD
- Q3 FY20222022-11-02EPS$-1.52 vs $-1.17-29.9%Rev$2.5M vs ——EODHD
- Q2 FY20222022-08-03EPS$-0.23 vs $-1.02+77.5%Rev$89.0M vs ——EODHD
- Q1 FY20222022-05-03EPS$-1.02 vs $-0.94-8.5%Rev$1.1M vs ——EODHD
- Q4 FY20212022-02-23EPS$-0.36 vs $-0.84+57.1%Rev$55.6M vs ——EODHD
- Q3 FY20212021-11-02EPS$-0.95 vs $-0.77-23.4%Rev$5.4M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-1.64 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $-1.67 | $-1.61 | -3.7% | $19.4M | — | — | EODHD |
| Q4 FY2025 | 2026-02-23 | $-1.50 | $-1.56 | +3.9% | $17.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-2.55 | $-1.57 | -62.4% | $1.9M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-1.12 | $-1.42 | +21.1% | $66.8M | — | — | EODHD |
| Q1 FY2025 | 2025-05-05 | $-1.36 | $-1.36 | +0.2% | $1.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-24 | $-1.26 | $-1.17 | -7.3% | $16.9M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-1.36 | $-1.25 | -8.8% | $463.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-1.31 | $-1.06 | -23.6% | $249.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-1.33 | $-1.14 | -16.7% | $835.0K | — | — | EODHD |
| Q4 FY2023 | 2024-02-26 | $-1.38 | $-0.97 | -42.3% | $1.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-1.35 | $-0.74 | -82.4% | $378.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-1.34 | $-1.15 | -16.5% | $867.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-1.38 | $-1.20 | -15.0% | $4.6M | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-1.45 | $-1.21 | -19.8% | $2.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-1.52 | $-1.17 | -29.9% | $2.5M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.23 | $-1.02 | +77.5% | $89.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-1.02 | $-0.94 | -8.5% | $1.1M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $-0.36 | $-0.84 | +57.1% | $55.6M | — | — | EODHD |
| Q3 FY2021 | 2021-11-02 | $-0.95 | $-0.77 | -23.4% | $5.4M | — | — | EODHD |
Source: EODHD. CYTK reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks CYTK's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.76 | $2.24 | +23.1% | +5.3% | +6.3% |
| Q4 FY2026 | $2.52 | $2.06 | +22.4% | +8.6% | +10.1% |
| Q3 FY2026 | $2.84 | $2.22 | +27.8% | +8.5% | +7.8% |
| Q2 FY2026 | $2.81 | $2.33 | +20.4% | +5.0% | +4.0% |
| Q1 FY2025 | $2.59 | $2.16 | +19.7% | +5.7% | +3.8% |
| Q4 FY2025 | $2.77 | $2.16 | +28.3% | +4.2% | +6.7% |
| Q3 FY2025 | $2.86 | $2.41 | +18.7% | +6.6% | +6.5% |
| Q2 FY2025 | $2.74 | $2.19 | +24.9% | +8.0% | +6.6% |
| Q1 FY2024 | $3.05 | $2.49 | +22.4% | -1.0% | -1.3% |
| Q4 FY2024 | $2.83 | $2.46 | +15.2% | -1.4% | +1.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Robert A. BlumCEO3 mo20 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- Sung LeeCFO3 mo7 callsCurrentSample
CFO since 2026 • 2/2 beats (100%) • last guidance cut Q2 FY2026
- Andrew CallosEVP, Chief Commercial Officer4 mo20 callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- Fady Ibraham MalikEVP Research & Development3 mo2 callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- Jeffrey HessekielChief Legal & Admin Officer3 mono recorded callsCurrentSample
OTHER since 2026 • 2/2 beats (100%) • last guidance raise Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CYTK.
$ curl https://api.spokenalpha.com/v1/companies/CYTKFAQ
Frequently asked about CYTK
Where can I find CYTOKINETICS INC's (CYTK) earnings call transcripts?
Spoken Alpha indexes CYTK's earnings call transcripts at https://spokenalpha.com/companies/CYTK. Each call links to attributed speakers and parsed analyst Q&A. CYTOKINETICS INC's own investor relations page is at https://ir.cytokinetics.com/overview/default.aspx.
When was CYTOKINETICS INC's most recent earnings call?
CYTOKINETICS INC (CYTK) held its most recent earnings call on 2026-05-05, covering fiscal Q1 2026.
What sector is CYTK in?
CYTOKINETICS INC (CYTK) operates in the Healthcare sector (Biotechnology industry).